

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

Serial No. : 10/537,117
 Applicants : Daisuke AWAKURA et al.
 Filed : July 1, 2005
 For : METHODS AND COMPOSITIONS
 FOR INHIBITING MYCOTOXIN
 CONTAMINATION IN CEREALS
 Art Unit : 1612
 Examiner : Marcos L. SZNAIDMAN
 Docket No. : 09021/HG
 Confirm No. : 8343
 Customer No.: 01933

Express Mail Mailing Label
 No.: EM 268 107 249 US
 Date of Deposit: July 15, 2009

I hereby certify that this paper is
 being deposited with the United States
 Postal Service "Express Mail Post
 Office to Addressee" service under
 37 CFR 1.10 with sufficient postage
 on the date indicated above and is
 addressed to:
 MAIL STOP PCT
 Commissioner for Patents,
 P.O. Box 1450
 Alexandria, VA 22313-1450


 Dorothy DeFrancesco

In the event that this Paper is late
 filed, and the necessary petition
 for extension of time is not filed
 concurrently herewith, please consider
 this as a Petition for the requisite
 extension of time, and to the extent
 not tendered by Form PTO-2038 attached
 hereto, authorization to charge the
 extension fee, or any other fee
 required in connection with this
 Paper to Account No. 06-1378.

SUBMISSION OF CORRECTED TRANSLATION OF PCT APPLICATION

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

MAIL STOP PCT

S I R :

This application is a national phase application under 35
 USC 371 of PCT/JP2003/015543.

A NOTICE OF ACCEPTANCE UNDER 35 U.S.C. 371 AND 37 CFR 1.495
 dated November 4, 2005 was received in the above-identified
 application.

Submitted concomitantly herewith is a corrected English-
 language translation of the International Application as filed.
 Please substitute the enclosed English-language translation for

the English-language translation of International Application PCT/JP2003/015543 as filed, which was submitted on June 1, 2005.

The enclosed English-language translation is the same as the English-language translation submitted on June 1, 2005, except for the following changes:

In the Specification:

Page 3, line 12, "1,2,4-triazole-1-ylmethyl)pentane-3-ol" was changed to -- 1,2,4-triazol-1-ylmethyl)-pentan-3-ol --;

line 12, "generic" was changed to --common--;

line 13, "tebuconazol" was changed to --tebuconazole--;

lines 13-14, "dimethyl-1-(1-H-1,2,4-tiriazole-1-ylmethyl)" was changed to -- dimethyl-1-(1-H-1,2,4-triazol-1-ylmethyl) --;

line 14, "generic" was changed to --common--;

line 15, "metconazol" was changed to --metconazole--;

line 16, "3-dioxolane-2-ylmethyl)-1H-1,2,4-tirazole" was changed to -- 3-dioxolan-2-ylmethyl)-1H-1,2,4-triazole --;

line 16, "generic" was changed to --common--;

line 17, "propiconazol" was changed to --propiconazole--;

line 24, "generic" was changed to --common--;

line 26, "generic" was changed to --common--;

line 32, "bacteria" was changed to --fungi--.

line 35, "generic" was changed to --common--.

Page 4, line 2, "bacteria" was changed to --fungi--.

Page 7, line 3, "generic" was changed to --common--;

line 33, "generic" was changed to --common--.

Page 8, line 8, "generic" was changed to --common--;

line 19, "tebuconazol" was changed to --tebuconazole--;

line 20, "propiconazol" was changed to --propiconazole--;

line 22, "tebuconazol" was changed to --tebuconazole--.

Page 10, line 20, "generic" was changed to --common--.

Page 15, Table 3, column 3, "Tebuconazol" was changed to

--Tebuconazole--;

column 3, "Metconazol" was changed to

--Metconazole--;

column 3, "Propiconazol" was changed to

--Propiconazole--.

Page 17, Table 4, column 3, "Tebuconazol" was changed to
--Tebuconazole--;
column 3, "Propiconazole" was changed to
--Propiconazole--;
column 3, Trifloxistrobin" was changed to
--Trifloxystrobin--.

Page 18, line 5, "bacterial" was changed to --fungal--.

Page 19, line 10, "bacterial" was changed to --fungal--;
line 16, "bacteria" was changed to --fungi--.

Page 20, line 1, "bacteria" was changed to --fungi--;
line 3, "bacterial" was changed to --fungal--;
line 17, "bacterial" was changed to --fungal--;
line 24, "bacteria" was changed to --fungi--;
line 26, "bacterial" was changed to --fungal--.

Page 21, line 3, "bacterial" was changed to --fungal--;
line 11, "bacteria" was changed to --fungi--;
line 20, "pathological" was changed to
--pathogenic--.

In the Claims:

Claim 7, line 3, "tebuconazol" was changed to

--tebuconazole--;

line 4, "metconazol" was changed to

--metconazole--; and "propiconazol" was

changed to --propiconazole--;

line 5, "trifloxistrobin" was changed to


--trifloxystrobin--.

Enclosed is a Form PTO-2038 in the amount of \$130 for the required processing fee.

If necessary, please treat this paper as a Petition Under 37 CFR 1.181 or 37 CFR 1.182.

If necessary, please charge any additional fees to Deposit
Account No. 06-1378.

Respectfully submitted,



RICHARD S. BARTH

REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.
220 FIFTH AVENUE, 16th FLOOR
NEW YORK, NEW YORK 10001-7708
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Enclosures: (1) corrected English-language translation
of International Application PCT/JP2003/015543

(2) Form PTO-2038 in the amount of \$130